What is the ARDS Market Report?
Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition, was described as a form of respiratory failure that closely resembled respiratory distress syndrome in infants. It can be caused by a variety of pulmonary (such as pneumonia, aspiration) or non-pulmonary (like sepsis, pancreatitis, and trauma) abuses, leading to the development of non-hydrostatic pulmonary edema.
ARDS is characterized by an acute, diffuse, inflammatory lung injury, leading to increased alveolar-capillary permeability, increased lung weight, and loss of aerated lung tissue. Clinically, this establishes hypoxemia, with bilateral opacities on chest radiography, associated with reduced lung compliance and increased venous admixture and physiological dead space. Morphologically, diffuse alveolar damage is observed in the acute phase of ARDS.
As per the analysis, in terms of severity-specific incidence, a similar trend is observed in all countries, with a majority of the cases witnessed for moderate ARDS, except France, where severe cases of ARDS accounted for a maximum patient population.
What is the ARDS Market Size?
The therapeutic market of Acute Respiratory Distress Syndrome (ARDS) in the seven major markets was USD 917.81 Million in 2017. The United States accounts for the highest market size of Acute Respiratory Distress Syndrome (ARDS), in comparison to the other seven major markets, i.e., EU5 countries and Japan. Among the EU5 countries, Germany contributed the largest market share in EU5 countries, with 52.02%, followed by Italy (15.68%).
Original Source:- ARDS Market
